January 28, 2025

Zacks Small-Cap Research

*Sponsored – Impartial - Comprehensive*

Brad Sorensen, CFA
312-265-9574
bsorensen@zacks.com

scr.zacks.com

10 S. Riverside Plaza, Chicago, IL 60606

# Telomir Pharmaceuticals (TELO-NASDAQ)

## TELO: Exciting and Expansive Potential from Test Results

Telomir is developing a treatment that has the potential to lead to the extension of human life and solve many age-related health issues. We value TELO at $12.15 using discounted cash flow analysis.

## OUTLOOK

Telomir Pharmaceuticals is a preclinical stage company focused on the science of lengthening telomere caps, which the company believes will extend human lifespans and improve quality of life as people age.

Preclinical tests showed that the company's signature therapy, Telomir-1, demonstrated the ability to reverse oxidative stress, which plays a central role in a variety of diseases.

| | |
|---|---|
| Current Price (01/27/25) | $4.75 |
| **Valuation** | **$12.15** |

## SUMMARY DATA

| | |
|---|---|
| **52-Week High** | **$11.90** |
| **52-Week Low** | **$3.31** |
| **One-Year Return (%)** | **N/A** |
| **Beta** | **N/A** |
| **Average Daily Volume (sh)** | **95,352** |
| **Shares Outstanding (mil)** | **30** |
| **Market Capitalization ($mil)** | **$141** |
| **Short Interest Ratio (days)** | **N/A** |
| **Institutional Ownership (%)** | **0** |
| **Insider Ownership (%)** | **N/A** |
| **Annual Cash Dividend** | **$0.00** |
| **Dividend Yield (%)** | **0.00** |
| **5-Yr. Historical Growth Rates** | |
| **Sales (%)** | **N/A** |
| **Earnings Per Share (%)** | **N/A** |
| **Dividend (%)** | **N/A** |

| | |
|---|---|
| **Risk Level** | **High,** |
| **Type of Stock** | **Small-Growth** |
| **Industry** | **N/A** |

## ZACKS ESTIMATES

**Revenue**
(in millions of $)

| | Q1 (Mar) | Q2 (Jun) | Q3 (Sep) | Q4 (Dec) | Year (Dec) |
|---|---|---|---|---|---|
| 2023 | 0 A | 0 A | 0 A | 0 A | 0 A |
| 2024 | 0 A | 0 A | 0 A | 0 E | 0 E |
| 2025 | 0 E | 0 E | 0 E | 0 E | 0 E |
| 2026 | 0 E | 0 E | 0.5 E | 1.0 E | 1.5 E |

**Earnings per share**

| | Q1 (Mar) | Q2 (Jun) | Q3 (Sep) | Q4 (Dec) | Year (Dec) |
|---|---|---|---|---|---|
| 2023 | NA | NA | NA | NA | -0.45 A |
| 2024 | -0.23 A | -0.06 A | -0.20 A | -0.05 E | -0.54 E |
| 2025 | -0.06 E | -0.05 E | -0.04 E | -0.08 E | -0.23 E |
| 2026 | -0.03 E | -0.04 E | -0.06 E | -0.05 E | -0.18 E |

© Copyright 2025, Zacks Investment Research. All Rights Reserved.

## UPDATE

Telomir Pharmaceuticals is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA's protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company's primary therapy, can lengthen telomeres and initial animal testing illustrates the potential impact. In fact, the company recently released results from one of those tests, which, according to CEO Erez Aminov, "confirms Telomir-1 can reverse biologic aging, extending life while preserving health."

The company just released potential groundbreaking results from a preclinical study of Telomir-1 on human cell lines. Data from the test showed the ability of Telomir-1 to "fully reverse copper-induced elevation of Reactive Oxygen Species (ROS) and provided robust cellular protection against copper toxicity."

Oxidative stress occurs when there is an imbalance between free radicals (ROS) and antioxidants in the body, leading to cellular damage. Free radicals are unstable molecules that can harm proteins, DNA, and cell membranes, while antioxidants help neutralize them. This imbalance can contribute to aging and is implicated in the development of various diseases. Oxidative stress plays a key role in chronic conditions such as cardiovascular diseases (e.g., atherosclerosis and hypertension), neurodegenerative disorders (e.g., Alzheimer's disease and Parkinson's disease), diabetes, cancer, and inflammatory diseases like rheumatoid arthritis. It is also linked to complications in conditions like chronic obstructive pulmonary disease (COPD) and kidney disease.

Telomir is evaluating Telomir-1 for the treatment of viral infections as well, such as avian influenza, otherwise known as bird flu, where oxidate stress is a key factor in disease severity. Viral infections trigger and exploit excessive ROS production as a mode to facilitate their replication, leading to widespread inflammation, cellular damage, and impaired immune responses. This oxidative damage exacerbates disease progression and increases the risk of severe outcomes.

According to the company, there are currently no approved drugs specifically targeting the oxidative stress caused by the bird flu or similar viruses. Telomir-1's ability to reverse oxidative stress and protect cells offers a promising avenue for addressing this gap. By mitigating the cellular damage associated with oxidative stress, Telomir-1 has the potential to play a critical role in reducing the severity of such infections.

This announcement adds to the list of conditions that Telomir-1 has the potential to treat by attacking the underlying causes of the conditions and not just the symptoms. The company is continuing to zero in on all of the mechanisms that cause Telomir-1 to have these positive impacts and recently explained that Telomir-1 is designed to normalize iron homeostasis, reducing oxidative stress and improving insulin sensitivity, setting it apart from existing drugs that primarily treat symptoms without addressing these underlying causes. Excess iron levels contribute to oxidative stress, beta-cell damage, and insulin resistance across key tissues and reducing these levels could have a major impact on a wide variety of conditions.

It's this extensive experience and record of success, combined with the test results we've seen at this stage of the process that makes us get excited about the potential for Telomir-1 and the company that develops it. We urge investors who have a higher risk tolerance to take a look at TELO and consider


investing in a company at an early stage that has a large potential upside, with a low float and positive news flow likely in the near future, providing potential fuel to the stock.

## PROJECTED INCOME STATEMENT & BALANCE SHEET

**Telomir Pharmaceuticals Income Statement and Balance Sheet**

| | 2023A | 1Q2024A | 2Q2024A | 3Q2024A | 4Q2024E | 2025E | 2026E |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 1,500,000 |
| Operating Costs: | | | | | | | |
| General and Admistrative | (600,192) | (741,541) | (879,695) | (5,378,744) | (897,289) | (2,966,164) | (2,995,826) |
| Related party travel costs | (1,767,550) | (370,500) | (377,910) | 0 | 0 | (1,482,000) | (1,496,820) |
| Research and Development | (1,574,306) | (804,023) | (594,801) | (627,434) | (639,983) | (2,559,931) | (2,687,927) |
| Total Operating Gain/(Loss) | (3,942,048) | (1,916,064) | (1,852,406) | (6,006,178) | (1,537,272) | (7,008,095) | (5,680,573) |
| Interest Income/(expenses) | (1,643,049) | (4,338,543) | 25,493 | 15,445 | 15,599 | 62,398 | 65,518 |
| Loss on extingushment of debt | (7,486,767) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/(Expenses) | - | - | - | - | - | - | - |
| Net Gain/(Loss) | (13,071,864) | (6,254,607) | (1,826,913) | (5,990,733) | (1,521,672) | (6,945,697) | (5,615,055) |
| Diluted loss per share | (0.45) | (0.23) | (0.06) | (0.20) | (0.05) | (0.23) | (0.18) |
| Diluted Wtd Common Shares Outstanding | 29,017,857 | 27,768,156 | 29,609,814 | 29,609,814 | 29,905,912 | 30,204,971 | 30,507,021 |
| Assets | | | | | | | |
| Current Assets | | | | | | | |
| Cash and cash equivalents | 1,231 | 3,274,314 | 1,883,909 | 834,638 | 842,984 | 851,414 | 859,928 |
| Other Assets | 433,994 | 228,808 | 217,813 | 207,347 | 209,420 | 211,515 | 213,630 |
| Total Current Assets | 435,225 | 3,503,122 | 2,101,722 | 1,041,985 | 1,052,405 | 1,062,929 | 1,073,558 |
| Long Term Assets | 4,338,543 | - | - | - | - | - | - |
| Total Assets | 4,773,768 | 3,503,122 | 2,101,722 | 1,041,985 | 1,052,405 | 1,062,929 | 1,073,558 |
| Current Liabilities | | | | | | | |
| Trade accounts payable | 707,187 | 478,650 | 393,814 | 506,479 | 349,471 | 241,135 | 166,383 |
| Other Current Liabilities | 628,377 | 7,902 | 140,341 | 93,432 | 94,366 | 95,310 | 96,263 |
| Total Current Liabilities | 1,335,564 | 486,552 | 534,155 | 599,911 | 443,837 | 336,445 | 262,646 |
| Long-term Liabilities | - | - | - | - | - | - | - |
| Total Liabilities | 1,335,564 | 486,552 | 534,155 | 599,911 | 443,837 | 336,445 | 262,646 |
| Common Stock | - | - | - | - | - | - | - |
| Additional Paid-in Capital | 17,502,346 | 23,335,319 | 23,335,319 | 28,140,559 | 28,421,965 | 28,706,184 | 28,993,246 |
| Accumulated Deficit | (14,064,142) | (20,318,749) | (21,767,752) | (27,698,485) | (27,813,397) | (27,979,700) | (28,182,334) |
| Total SH deficit/(equity) | 3,438,204 | 3,016,570 | 1,567,567 | 442,074 | 608,568 | 726,484 | 810,912 |
| Total Liabilities and SH deficit/(equity) | 4,773,768 | 3,503,122 | 2,101,722 | 1,041,985 | 1,052,405 | 1,062,929 | 1,073,558 |

## HISTORICAL STOCK PRICE



## DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Brad Sorensen, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.